Findings

What do systematic reviews say?

1,970 questions · 2,433 findings · 231 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 303 · 12.5%GRADE not reported 759 · 31.2%Very low 357 · 14.7%Low 476 · 19.6%Moderate 418 · 17.2%High 120 · 4.9%

MX exercise training vs control

Fatigue · patients with fibromyalgia

1 finding from 1 review

Mixed exercise training for adults with fibromyalgia 2019 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 493 participants
Moderate

MX exercise training vs control

Stiffness · patients with fibromyalgia

1 finding from 1 review

Mixed exercise training for adults with fibromyalgia 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 261 participants
Low

MX exercise training vs control

Physical function · patients with fibromyalgia

1 finding from 1 review

Mixed exercise training for adults with fibromyalgia 2019 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 477 participants
Moderate

MX exercise training vs control

Withdrawal (all‐cause) · patients with fibromyalgia

MX exercise training showed no clear difference in all‐cause withdrawal All‐cause withdrawals from studies Median… compared with control (moderate certainty).

1 finding from 1 review

Mixed exercise training for adults with fibromyalgia 2019 · Cochrane Headline outcomes only
RR 1.02 [0.69, 1.51]
19 studies · 1065 participants
Moderate

MX exercise training vs control

Adverse events ‐ increase in symptoms, injuries, or serious adverse events · patients with fibromyalgia

1 finding from 1 review

Mixed exercise training for adults with fibromyalgia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Chlorhexidine 0.2% vs Pre-treatment (baseline, same group)

Plaque · Medically healthy individuals (adults and children, 6-60 years)

0.2% chlorhexidine rinse reduced plaque relative to baseline; not GRADE-rated.

1 finding from 1 review

The antiplaque/anticariogenic efficacy of Salvadora persica (Miswak) mouthrinse in comparison to that of… 2019 All outcomes
Pre- vs post-treatment · In vivo clinical trial (human oral cavity) · Chlorhexidine concentration: 0.2%
MD 0.45 [0.19, 0.70]
10 studies · 282 participants
GRADE not reported

One week of AmBd + 5FC vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.62 [0.42, 0.93]
1 study · 228 participants
Moderate

Two weeks of AmBd + FLU + steroids vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + FLU + steroids showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (high certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.15 [0.93, 1.42]
1 study · 450 participants
High

One week of AmBd + FLU vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.18 [0.88, 1.58]
1 study · 225 participants
Moderate

One week of AmBd + FLU vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.27 [0.94, 1.72]
1 study · 226 participants
Moderate

One week of AmBd + FLU vs two weeks of 5FC + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU probably leads to higher mortality: 10 weeks compared with two weeks of 5FC + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.39 [1.07, 1.8]
1 study · 336 participants
Moderate

Two weeks of FLU vs two weeks of 5FC + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of FLU changes mortality: 10 weeks compared with two weeks of 5FC + FLU (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.46 [0.96, 2.23]
2 studies · 98 participants
Very low

Two weeks of L‐AmB vs two weeks of AmBd

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of L‐AmB changes mortality: 10 weeks compared with two weeks of AmBd (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.43 [0.04, 4.25]
1 study · 28 participants
Very low

Short‐course L‐AmB + FLU vs two weeks of L‐AmB + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Short‐course L‐AmB + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of L‐AmB + FLU (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.03 [0.47, 2.25]
1 study · 79 participants
Low

Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + 5FC (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 2.81 [0.33, 24.16]
1 study · 31 participants
Very low

Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + FLU (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.43 [0.13, 1.37]
1 study · 32 participants
Very low

Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1 [0.24, 4.23]
1 study · 32 participants
Very low

One week of AmBd + 5FC vs two weeks of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.58 [0.39, 0.86]
1 study · 227 participants
Moderate

One week of AmBd + 5FC + FLU vs one week of AmBd + FLU

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC + FLU showed no clear difference in mortality: 10 weeks compared with one week of AmBd + FLU (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.86 [0.35, 2.1]
1 study · 40 participants
Low

Two weeks of AmBd + 5FC + IFNg vs two weeks of AmBd + 5FC

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + 5FC + IFNg showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.92 [0.48, 1.77]
1 study · 88 participants
Low